This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Stryker Shares May Gain on the Completion of the Acquisition of NICO
by Zacks Equity Research
SYK completes the acquisition of NICO to strengthen its portfolio of solutions for tumor resection and the treatment of ICH.
DGXNegative Net Change UHSPositive Net Change SYKNegative Net Change ABMNegative Net Change
medical medical-devices
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
by Zacks Equity Research
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.
AZNNegative Net Change PFEPositive Net Change MRKNegative Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
by Zacks Equity Research
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
REGNNegative Net Change SNYPositive Net Change BMYPositive Net Change JNJNegative Net Change
biotechs medical pharmaceuticals
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe
by Zacks Equity Research
AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.
ANGONegative Net Change UHSPositive Net Change AVAHPositive Net Change ATIPNegative Net Change
medical medical-devices
TNDM Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.
AXGNPositive Net Change TNDMNegative Net Change KIDSNegative Net Change TMDXNegative Net Change
medical medical-devices
EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock
by Zacks Equity Research
When combined with EDAP's Focal One platform, Avenda's Unfold AI enables more accurate and patient-specific treatment options.
EDAPPositive Net Change AXGNPositive Net Change KIDSNegative Net Change TMDXNegative Net Change
medical
TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU
by Zacks Equity Research
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.
BSXNegative Net Change LLYPositive Net Change PAHCPositive Net Change TNDMNegative Net Change
medical medical-devices
Take the Zacks Approach to Beat the Markets: Phibro Animal Health, Travelzoo, Ollie's Bargain Outlet in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
AMTNegative Net Change PSANegative Net Change PHMNegative Net Change ORCLNegative Net Change PAHCPositive Net Change FINegative Net Change OLLINegative Net Change AXONNegative Net Change NOBLPositive Net Change SBFGNegative Net Change TZOONegative Net Change SOLVNegative Net Change
business-services computers construction consumer-staples finance industrial-products medical reit retail
New Strong Buy Stocks for September 23rd
by Zacks Equity Research
OPRA, SBSI, AU, AHR and LYTS have been added to the Zacks Rank #1 (Strong Buy) List on September 23, 2024.
AUNegative Net Change SBSINegative Net Change LYTSNegative Net Change OPRAPositive Net Change AHRPositive Net Change
medical
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
UHSPositive Net Change CORNegative Net Change AVAHPositive Net Change ATIPNegative Net Change
medical medical-devices
Longboard Stock Soars on FDA Designations for Epilepsy Drug
by Zacks Equity Research
The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.
ILMNNegative Net Change KRYSNegative Net Change BVSPositive Net Change LBPHNegative Net Change
biotechs medical
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
by Zacks Equity Research
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
AZNNegative Net Change JNJNegative Net Change ILMNNegative Net Change KRYSNegative Net Change
biotechs medical pharmaceuticals
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
by Zacks Equity Research
Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.
DGXNegative Net Change UHSPositive Net Change SNNPositive Net Change ABMNegative Net Change
medical medical-devices
UnitedHealth at 19.09X P/E: Worth the Price or Time to Take Profits?
by Kaibalya Pravo Dey
With expansion into targeted markets and strategic diversification, UNH still has significant growth potential left.
UNHPositive Net Change HUMPositive Net Change CINegative Net Change
hmo medical
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
GE HealthCare Shares Rise After AI-Powered Venue Sprint's Launch
by Zacks Equity Research
GEHC introduces Venue Sprint, a portable AI-enabled ultrasound device offering wireless probes, real-time insights and advanced clinical tools for improved care.
UHSPositive Net Change AVAHPositive Net Change ATIPNegative Net Change GEHCPositive Net Change
medical medical-devices
How HCA Healthcare (HCA) Stock Stands Out in a Strong Industry
by Zacks Equity Research
HCA Healthcare (HCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
HCANegative Net Change
medical
Roche Antiviral Drug Reduces Transmission in Late-stage Study
by Zacks Equity Research
Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.
RHHBYPositive Net Change PFEPositive Net Change LLYPositive Net Change BAYRYPositive Net Change
biotechnology medical pharmaceuticals
Do Options Traders Know Something About Enhabit (EHAB) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Enhabit (EHAB) stock based on the movements in the options market lately.
EHABNegative Net Change
medical
New Strong Sell Stocks for September 20th
by Zacks Equity Research
AMKR, BW and AMFPF have been added to the Zacks Rank #5 (Strong Sell) List on September 20 2024.
AMKRNegative Net Change BWPositive Net Change AMFPFNegative Net Change
computers medical semiconductor
Implied Volatility Surging for Tactile Systems (TCMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Tactile Systems (TCMD) stock based on the movements in the options market lately.
TCMDNegative Net Change
medical medical-devices
BiomX Stock Gains From Favorable Study Data Presentation on BX004
by Zacks Equity Research
PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept. 28.
AXGNPositive Net Change KIDSNegative Net Change TMDXNegative Net Change PHGEPositive Net Change
medical
4 Stocks to Buy Amid Dental Supplies Industry Challenges
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
BDXPositive Net Change MCKNegative Net Change COONegative Net Change STAAPositive Net Change
medical medical-devices
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
by Zacks Equity Research
Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.
BSXNegative Net Change ALCPositive Net Change AXGNPositive Net Change PAHCPositive Net Change
medical medical-devices
DGX Stock to Benefit From New Partnership With Sentara Health Plans
by Zacks Equity Research
Quest Diagnostics extends services in Virginia and Florida via a partnership with Sentara Health Plans.
BSXNegative Net Change DGXNegative Net Change AXGNPositive Net Change PAHCPositive Net Change
medical medical-devices